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Introduction {#sec001}
============

Chronic kidney disease (CKD) is traditionally considered an unremittingly progressive disease and early identification of risk factors predicting faster CKD progression is the centerpiece of current guidelines \[[@pone.0140138.ref001]\]. CKD regression is considered as an uncommon outcome in these patients. However, solid evidence in experimental models and patients exists that renal damage may regress \[[@pone.0140138.ref002],[@pone.0140138.ref003]\].

In the Afro-American Study of Kidney Disease (AASK) trial, a tiny minority (3.3%) of patients exhibited positive slopes of Iothalamate-measured GFR (+1.06 ml/min/1.73m^2^) which could not be explained by random measurement variation \[[@pone.0140138.ref004]\]; similarly, in a subgroup of 406 patients selected among the 1,269 enrolled in the NEPHROTEST study with at least three available ^51^Cr-EDTA renal clearance measurements, 15% of patients manifested a GFR improvement over time \[[@pone.0140138.ref005]\]. However, the peculiar risk profile of African Americans and the highly selected nature of the NEPHROTEST sub-cohort, in which 70% of participants with less than three GFR measurements were excluded, may limit the generalizability of these estimates of CKD regression. Similarly, these two studies provided only few data on the demographic, clinical and biochemical factors which associate with eGFR improvement over time \[[@pone.0140138.ref004],[@pone.0140138.ref005]\]. More important, the prognostic role of CKD regression was not addressed in these studies. The issue is of major relevance because recent studies, primarily designed to assess the relationship between the decline of renal function and mortality, reported that CKD patients showing eGFR increase over follow up do exhibit a clear-cut trend toward higher mortality \[[@pone.0140138.ref006]--[@pone.0140138.ref009]\].

We therefore evaluated GFR changes over time in 1,418 adult patients with CKD stage 3--4 receiving renal care in the clinics networks of two cohort studies in Italy, the TArget Blood pressure LEvels (TABLE) study and Multiple intervention and AUdit in Renal diseases to Optimize care (MAURO) study \[[@pone.0140138.ref010],[@pone.0140138.ref011]\]. The study is aimed at defining the prevalence of CKD regressors, correlates associated with this condition and the prognostic role of CKD regression for the risk of ESRD and mortality.

Methods {#sec002}
=======

Study design and selection criteria {#sec003}
-----------------------------------

This is a multicenter cohort study involving forty-seven Italian renal clinics which participated into two cohorts studies \[[@pone.0140138.ref010],[@pone.0140138.ref011]\]. Study protocol was in conformity with ethical guidelines of our institutions, and it was approved by ethics committees of Second University of Naples for TABLE study and of Center of National Research-Institute of Biomedicine and Molecular Immunology Hospital of Reggio Calabria for MAURO study; then was approved by local ethics committees of all nephrology units that participated to the study. Written informed consent was obtained from each patient. Participating centers shared renal care protocols adhering to International and National CKD Guidelines \[[@pone.0140138.ref012],[@pone.0140138.ref013]\].

We pooled individual patients' data of the two cohorts \[[@pone.0140138.ref014]\]. The first cohort was the TABLE cohort constituted by consecutive CKD patients with eGFR\<60 ml/min/1.73m² enrolled in 25 renal clinics during 2003. All patients in this cohort had a fully recorded first visit at the same renal clinics with a diagnosis of CKD dating back at least 1 year before recruitment \[[@pone.0140138.ref010]\]. Main inclusion criteria were absence of acute changes of eGFR ≥30% in the six months before selection, kidney transplant, pregnancy and cancer or diseases in the terminal phase~~.~~ The second cohort (MAURO) was composed of consecutive adult patients with serum creatinine 132--354 mmol/dl (if males) and 115--309 mmol/dl (if females), recruited between October 2005 and November 2007 in 22 renal clinics on the basis of selection criteria similar to TABLE study. As previously described, the main inclusion criteria of the MAURO study were: at least 2 measurements of of eGFR during the run-in period; non-acute or rapidly evolving renal disease; non transplanted, not pregnant, not affected by cancer or disease in a terminal phase \[[@pone.0140138.ref011]\].

Two phases were planned. In the first phase, from baseline to follow-up visit lasting 18--24 months, we ascertained the status of \"regressor\" by calculating the rate of change of kidney function over time (ΔGFR). This was estimated as the absolute difference of eGFR between the baseline and the follow-up visit (occurring in the period between 18 and 24 months from baseline visit) and expressed as ml/min/1.73 m^2^/year. Patients deceased or dropped out in the same period were excluded from analyses. In the second phase of the study, lasting from the follow-up visit to the date of death, ESRD or last available visit, we assessed the survival difference between regressors and non-regressors.

Patients\' classification {#sec004}
-------------------------

According to the CKD Prognosis Consortium \[[@pone.0140138.ref015]\], we selected in each cohort patients with eGFR 60--15 ml/min/1.73m^2^, with at least two measurements of eGFR and the last measurement obtained 18--24 months after baseline. We defined as "regressors" those patients who experienced a ΔGFR ≥0 ml/min/1.73 m^2^/year. Indeed, since a physiological decline of about -1 ml/min/1.73 m^2^/year has been demonstrated in healthy adults \[[@pone.0140138.ref016]--[@pone.0140138.ref018]\], stability of eGFR over time can be still considered as an improvement of kidney function. Those with ΔGFR \<0 ml/min/1.73 m^2^/year or those who developed ESRD over the same follow up were classified as "non regressors".

Data Collection {#sec005}
---------------

At the baseline visit, we collected demographics, medical history, office BP, laboratory parameters, including 24-h-urinary proteinuria, and therapy. Cigarette smoking was dichotomized as current smoker and non-smoker. Office BP was measured according to recommendations by the European Society of Hypertension by using standard mercury sphygmomanometers \[[@pone.0140138.ref019]\].

Diabetes was defined by either self-reported history of diagnosis, use of hypoglycemic drugs, or a fasting glucose level\>126 mg/dl. Cardiovascular disease (CVD) was defined as electrocardiography-documented angina, history of myocardial infarction, stroke, transient ischemic attack, intermittent claudication, and prior revascularization procedures. Laboratory parameters were measured by standard methods in the clinical laboratories of participating centers. Office BP, laboratory data and therapy were also collected at follow up visit. All laboratories adhered to regional or national quality control programs.

Estimated GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2009 creatinine equation \[[@pone.0140138.ref020],[@pone.0140138.ref021]\]; the creatinine measurement was not standardized to isotope dilution mass spectrometry, so that the creatinine concentrations were reduced by 5% (the established calibration factor) \[[@pone.0140138.ref022]\]. Twenty-four hour urine collection was repeated if the measured creatinine excretion rate was outside the 60% to 140% range of the value calculated according to Dwyer and Kenler \[[@pone.0140138.ref023]\].

Outcome of survival analysis {#sec006}
----------------------------

Study endpoints were ESRD and all-cause mortality before ESRD. Follow-up for either outcome started after the follow-up visit and lasted until June 30, 2011. ESRD date was the beginning of chronic dialysis or pre-emptive kidney transplantation. All participating centers were requested to follow the same procedure: to ascertain ESRD/death of patient phone calls to family members were made by local investigator when the patient missed two or more planned visits. Information on death, obtained by the family, was verified by death certificates provided by primary care physician of the patient. ESRD was also verified by means of medical records or regional dialysis registry.

Statistical analysis {#sec007}
--------------------

Continuous variables were reported as either mean±SD or median and interquartile range (IQR) according to their distribution and tested by means of unpaired Student t-test or Mann-Whitney. Categorical variables were reported as percentages and compared by using Pearson chi-squared test.

Logistic regression was used to identify basal factors associated with the regressor status. The model was built a priori by including age, gender, diabetes, BMI, CVD, smoking, cause of CKD, systolic BP, CKD stage, serum uric acid, hemoglobin, phosphate, and 24h proteinuria. The contribution of each covariate to the model fit was estimated as percentage reduction of R^2^ value of the model resulting, from omitting each variable in turn from the full model. We calculated R^2^ values according to Tjur approach \[[@pone.0140138.ref024]\]. Nonlinear association between proteinuria and eGFR improvement was found, and, therefore, a restricted cubic spline was used by Harrell approach \[[@pone.0140138.ref025]\] with four knots placed a priori at clinically relevant values (0, 0.5, 1 and 3 g/24h of proteinuria).

Median follow-up was estimated by the inverse Kaplan-Meier approach \[[@pone.0140138.ref026]\]. We used the Cox models to estimate event-specific hazard ratios (HRs) and 95% confidence intervals (CIs) of the regressor status. HRs were adjusted by age, gender, diabetes, BMI, previous CVD, smoking, and systolic BP, uric acid, Hb, phosphate, cholesterol and 24h proteinuria measured at follow up visit. In order to attenuate the bias due to the regression to the mean \[[@pone.0140138.ref027]\], the model was adjusted for CKD stages at follow up visit (stage 1--3a as reference, stage 3b and stage 4--5) rather than for eGFR. The nonlinear relationship of ΔGFR and outcomes (either ESRD or death) was evaluated using restricted cubic splines separately in CKD stages at follow up visit. Specifically, we placed 5 knots at 0.050, 0.275, 0.500, 0.725, and 0.950 quantiles of the ΔGFR, according Harrell method \[[@pone.0140138.ref025]\].

We also calculated the kappa-statistic measure of agreement in patients classification (regressors/non-regressors) when using ΔGFR over time (two points) or ordinary least-squares regression slope (from 3 to 5 points); agreement was classified according to Landis and Koch \[[@pone.0140138.ref028]\]. The data were analyzed using SAS version 9.2 (SAS Inc., Cary, NC).

Results {#sec008}
=======

As described in [Fig 1](#pone.0140138.g001){ref-type="fig"}, out of the 1727 eligible patients, 1418 were studied. In particular, the first cohort of patients was extracted from a population of 1025 CKD patients from TABLE study. Among these, 83 were excluded because they died after the enrollment but before 2^nd^ eGFR assessment, 97 were excluded because they dropped out of the study and 73 were excluded because they had missing eGFR values in the time windows 18--24 months. The source population of the second cohort included 646 CKD patients ([Fig 1](#pone.0140138.g001){ref-type="fig"}). We excluded 18 because they dropped out of the study, 22 because they died after the enrollment but before 2^nd^ eGFR assessment, and 16 because they had the second eGFR measurement before or after 18--24 months. Therefore, 1418 CKD patients were available for the data analysis. The comparison of baseline characteristics of 105 patients that died during this phase showed an older age (75.0±9.5 years) and greater prevalence of cardiovascular disease (48.6%) than that recorded in patients included into the study.

![Selection algorithm of patients.](pone.0140138.g001){#pone.0140138.g001}

All enrolled patients were Caucasian. They were characterized by a high proportion of older age (53.8% over 65 y), diabetes, previous CVD and smoking. At baseline, distribution of patients in CKD stage 3a, 3b, and 4 was 23.5%, 36.5% and 40.0%, respectively. The vast majority of patients (N = 1347, 94%) were on antihypertensive treatment: 23% were treated with one drug, 34% with two drugs, and 43% with three or more drugs. 1262 patients were treated with angiotensin-converting enzyme inhibitors and/or angiotenstin II blockers. Statins were used in one quarter of cohort, whereas use of fibrates was trivial (N = 8).

During the interval between baseline and follow-up visit (median: 23 months IQR 22--24), median ΔGFR was -1.7 ml/min/1.73m^2^/year (IQR from -4.6 to +0.8) for the whole cohort ([Table 1](#pone.0140138.t001){ref-type="table"}), without significant differences among the three stages (CKD-3a:-1.4 ml/min/1.73m^2^/year, IQR from -5.7 to 2.2; CKD-3b: -1.5 ml/min/1.73m^2^/year, IQR from -4.5 to 0.9; CKD-4: -2.0 ml/min/1.73 m^2^/year, IQR from -4.1 to -0.0, P = 0.246). On the basis of ΔGFR, we classified 391 patients as regressors (27.6%, 95%CI 25.3--30.0) and 1,027 as non-regressors (73.4%, 95%CI 70.1--74.8), including 111 patients who progressed to ESRD between baseline and follow up visit. In a sensitivity analysis, we re-assessed the prevalence of regressors in a nested cohort of 1154 patients (82% of the whole cohort) with at least three eGFR measurements in 24 months (range: 3--5) by using the ordinary least-squares regression slope. In this nested cohort, the prevalence of regressors was 29.6% with almost perfect agreement with the simultaneous two-points estimate in the whole cohort (Cohen's Kappa: 0.88; P\<0.0001).

10.1371/journal.pone.0140138.t001

###### Main demographic, clinical and therapeutic features of patients stratified by regressor status.

![](pone.0140138.t001){#pone.0140138.t001g}

                                  Overall                                                Regressors      Non-regressors                                           P
  ------------------------------- ------------------------------------------------------ --------------- -------------------------------------------------------- ----------
  ΔGFR (*ml/min/yr*)              -1.7 (-4.6/0.8)[\*](#t001fn002){ref-type="table-fn"}   2.4 (1.1/4.8)   -3.2(-5.4/-1.4)[\*\*](#t001fn003){ref-type="table-fn"}   
  Age (*years*)                   63.9±12.2                                              63.7±11.7       63.9±12.3                                                0.773
  Male Gender (%)                 59.0                                                   61.5            58.1                                                     0.227
  Diabetes (%)                    29.2                                                   24.9            30.8                                                     0.032
  Smokers (*%*)                   24.2                                                   26.3            23.4                                                     0.222
  History of CVD (*%*)            29.9                                                   27.5            30.0                                                     0.374
  BMI (*kg/m* ^*2*^)              27.8±4.7                                               28.1±4.7        27.7±4.7                                                 0.096
  Renal Disease (*%*)                                                                                                                                             0.001
  PKD                             6.1                                                    2.1             7.7                                                      
  Diabetic nephropathy            10.6                                                   8.2             11.6                                                     
  Hypertensive nephropathy        19.4                                                   20.6            18.9                                                     
  Glomerulonephritis              11.0                                                   11.1            11.0                                                     
  Other                           17.3                                                   18.9            16.7                                                     
  Unknown                         35.6                                                   39.0            34.0                                                     
  Systolic BP (*mmHg*)            137±18                                                 133±17          138±18                                                   \<0.0001
  Diastolic BP (*mmHg*)           79±11                                                  78±11           80±11                                                    0.005
  eGFR (*ml/min/1*.*73m* ^*2*^)   35±12                                                  38±12           34±12                                                    \<0.0001
  Proteinuria (*g/24 h*)          0.5 (0.2--1.1)                                         0.3(0.1--0.7)   0.6 (0.2--1.4)                                           \<0.0001
  Serum Albumin (*g/dl*)          4.0±0.5                                                4.1±0.5         4.0±0.5                                                  0.003
  Phosphate (*mg/dl*)             3.7±0.7                                                3.7±0.8         3.8±0.7                                                  0.017
  Uric Acid (*mg/dl*)             6.4±1.7                                                6.5±1.8         6.3±1.7                                                  0.130
  Hemoglobin (*g/dl*)             12.9±1.8                                               13.1±1.8        12.8±1.8                                                 0.001
  Cholesterol (*mg/dl*)           194±42                                                 193±40          194±43                                                   0.793
  Antihypertensives (n)           2.2±1.1                                                2.2±1.1         2.2±1.1                                                  0.381
  ACEIs/ARBs (*%*)                81.8                                                   81.3            81.9                                                     0.797
  ESA (*%*)                       8.8                                                    6.9             9.3                                                      0.140
  Statin (%)                      24.8                                                   27.9            23.8                                                     0.245

Data are mean±SD, percent or median (IQR).

\*delta eGFR was calculated in 1307 patients due to the exclusion of 111 patients who developed ESRD between baseline and follow up visit.

\*\* delta eGFR was calculated in 916 patients due to the exclusion of 111 patients who developed ESRD between baseline and follow up visit.

Abbreviations: BMI, body mass index; CVD, cardiovascular disease; eGFR, glomerular filtration rate estimated by the 4-variable MDRD equation; PKD, polycystic kidney disease; BP, blood pressure. ACEi, Angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blocker; ESA, erythropoiesis stimulating agents.

Regressors were characterized by a lower prevalence of diabetic nephropathy and PKD, lower BP, proteinuria and serum phosphate and higher serum albumin and hemoglobin ([Table 1](#pone.0140138.t001){ref-type="table"}). The prevalence of regressors from CKD stage 3a, 3b and 4 was 36.0%, 29.2% and 21.1%, respectively (P\<0.0001).

At the follow up visit, among non-regressors, serum phosphate increased while BP, hemoglobin, cholesterol and proteinuria declined. Of note, in regressors we observed a slight but significant increment of proteinuria ([Table 2](#pone.0140138.t002){ref-type="table"}). Median values of delta proteinuria were 0 g/day (IQR form -0.13 to 0.28) and 0 g/day (IQR from -0.44 to 0.26), respectively for regressors and non-regressors (p = 0.009).

10.1371/journal.pone.0140138.t002

###### Differences of clinical and laboratory parameters between baseline and follow up visit in regressors and non-regressors.

![](pone.0140138.t002){#pone.0140138.t002g}

                                 *Regressors*                    *Non-regressors*                                                                                                              
  ------------------------------ --------------- --------------- ------------------ ----------------------------------------------------- ---------------------------------------------------- ----------
  Systolic BP (*mmHg*)           134±17          133±15          0.399              137±18[^\#^](#t002fn002){ref-type="table-fn"}         134±17                                               \<0.0001
  Diastolic BP (*mmHg*)          78±11           77±9            0.187              80±11[^§^](#t002fn003){ref-type="table-fn"}           78±10                                                0.0002
  eGFR(*ml/min/1*.*73m* ^*2*^)   38±12           45±16           \-                 35±12[^\#^](#t002fn002){ref-type="table-fn"}          28±12[\*](#t002fn001){ref-type="table-fn"}           \-
  Proteinuria(*g/24 h*)          0.3(0.1--0.7)   0.4(0.1--0.8)   0.023              0.6 (0.2--1.4)[\*](#t002fn001){ref-type="table-fn"}   0.5(0.2--1.1)[\*](#t002fn001){ref-type="table-fn"}   0.004
  Serum Albumin (*g/dl*)         4.1±0.5         4.1±0.5         0.802              4.0±0.5[^\#^](#t002fn002){ref-type="table-fn"}        4.0±0.5[^§^](#t002fn003){ref-type="table-fn"}        0.936
  Phosphate(*mg/dl*)             3.7±0.8         3.7±0.9         0.197              3.7±0.7                                               3.9±0.9[^§^](#t002fn003){ref-type="table-fn"}        \<0.0001
  Uric Acid (*mg/dl*)            6.5±1.8         6.5±1.8         0.817              6.3±1.7                                               6.4±1.7                                              0.222
  Hemoglobin(*g/dl*)             13.1±1.8        13.0±1.8        0.488              12.9±1.7                                              12.6±1.7[\*](#t002fn001){ref-type="table-fn"}        \<0.0001
  Cholesterol (*mg/dl*)          193±40          184±39          0.002              194±42                                                185±44                                               \<0.0001

\*P\<0.0001 vs. regressors;

^\#^ p\<0.001 vs. regressors;

^§^p\<0.05 vs. regressors.

Abbreviations: FU: Follow up; eGFR, glomerular filtration rate estimated by the 4-variable MDRD equation; BP, blood pressure.

Predictors of regressor status are reported in [Table 3](#pone.0140138.t003){ref-type="table"}. Patients with higher BMI and lower levels of proteinuria and systolic BP were more likely regressors while patients with diagnosis of PKD had a lower probability of being regressors. In this analysis, more advanced CKD (stage 3b and stage 4) was not significantly associated to CKD regression ([Table 3](#pone.0140138.t003){ref-type="table"}). When estimating the hierarchy of prognostic factors by R² reduction, low proteinuria emerged as the strongest factor associated with eGFR improvement, accounting *per se* for 48% of the variance of the model. The non-linear relationship between proteinuria and the odds of the regressor status is depicted in [Fig 2](#pone.0140138.g002){ref-type="fig"}. The figure shows an exponential decrease of the likelihood of being regressor from lowest levels of proteinuria up to about 2 g/day with a plateau for values \>2 g/day. Furthermore, independent of proteinuria, PKD was associated with the lowest odds of CKD regression and this accounted for 20% of model variance.

10.1371/journal.pone.0140138.t003

###### Logistic regression analysis estimating factors associated with the probability of being regressor and estimated contribution of each determinant to model fit (% R^2^ reduction).

![](pone.0140138.t003){#pone.0140138.t003g}

                                           OR (95%)                                   P          \% R^2^ reduction
  ---------------------------------------- ------------------------------------------ ---------- -------------------
  Age (5 *years*)                          0.98 (0.93--1.05)                          0.622      0
  Male Gender (*yes versus not*)           1.27 (0.94--1.71)                          0.127      2
  Diabetes (*yes versus not*)              0.83 (0.58--1.20)                          0.328      1
  Smokers (*yes versus not*)               1.28 (0.94--1.74)                          0.116      2
  CVD (*yes versus not*)                   0.95 (0.71--1.28)                          0.742      0
  BMI (1 kg/m^2^)                          1.05 (1.02--1.08)                          0.001      8
  Renal Disease                                                                                  20
   Unknown                                 Ref.                                                  
   Diabetic nephropathy                    0.95 (0.55--1.65)                          0.863      
   Hypertensive nephropathy                0.96 (0.68--1.38)                          0.841      
   Glomerulonephritis                      1.06 (0.67--1.70)                          0.795      
   Other                                   0.96 (0.66--1.38)                          0.806      
   ADPKD                                   0.17 (0.08--0.40)                          \<0.0001   
  CKD Stages                                                                                     2
   3a                                      Ref.                                                  
   3b                                      0.90 (0.64--1.27)                          0.553      
   4                                       0.73 (0.53--1.09)                          0.106      
  Systolic BP (5 mmHg)                     0.94 (0.901--0.98)                         0.005      7
  Phosphate (mg/dl)                        1.05 (0.87--1.27)                          0.635      0
  Uric Acid (mg/dl)                        1.05 (0.98--1.14)                          0.186      0
  Hemoglobin (g/dl)                        1.03 (0.95--1.12)                          0.502      0
  ACEi and/or ARB use (*yes versus not*)   0.89 (0.64--1.24)                          0.490      0
  Proteinuria (mg/day)                     ---[\*](#t003fn001){ref-type="table-fn"}   \<0.0001   48

\*Non linear effect (p\<0.0001) as shown in [Fig 2](#pone.0140138.g002){ref-type="fig"}.

Abbreviations: BMI, body mass index; CV, cardiovascular; ADPKD, autosomal dominant polycystic kidney disease; CKD, Chronic Kidney Disease; BP, blood pressure. ACEi, Angiotensin converting enzyme inhibitor; ARB, Angiotensin II receptor blocker; ESA, erythropoiesis stimulating agents.

![Plots of odds ratios and 95% confidence intervals (as indicated by the curvilinear dash lines) for likelihood of being regressor by level of proteinuria as continuous variable (reference level, 0.5g/24h).\
The distribution of observations is shown as a rug plot on the x axis.](pone.0140138.g002){#pone.0140138.g002}

Survival analysis {#sec009}
-----------------

After the follow up visit (i.e., 18--24 months after baseline), 1307 patients were followed up for median time of 2.1 years (IQR: 1.0--3.2) to investigate the relationship of regressor status with the risk of ESRD and death. During this period, 173 ESRD events (all initiation of chronic dialysis treatment) and 110 deaths before ESRD occurred. Incidence rates were 7.6/100 patient-year (95% CI, 6.6 to 8.7) for ESRD and 3.6/100 patient-year (95% CI, 3.0 to 4.4) for death before ESRD.

Incidence rate for ESRD was markedly lower in regressors than in non-regressors (1.1 per 100 patient-year, 95% CI 0.6--2.2 and 10.4 per 100 patient-year, 95% CI 9.0--12.0, respectively) while no difference was detected for incidence of death (3.7 per 100 patient-year 95% CI, 2.5--5.2 and 3.7 per 100 patient-year, 95% CI 3.0--4.6 in regressors and non-regressors, respectively, P = 0.906). As compared to non regressors, ESRD risk was 72% lower in the subgroup of regressors while mortality risk did not differ ([Table 4](#pone.0140138.t004){ref-type="table"}). A significant effect of CKD stage was detected for the risk of ESRD but not for mortality ([Table 4](#pone.0140138.t004){ref-type="table"}). No interaction was found between regressors and CKD stage for both ESRD and all-cause death.

10.1371/journal.pone.0140138.t004

###### Cox analysis estimating the adjusted risk for ESRD and all-causes death of patients on the basis of regressor status and eGFR levels at the follow up visit.

![](pone.0140138.t004){#pone.0140138.t004g}

                                 HR      95%CI         P
  ------------------------------ ------- ------------- ----------
  **ESRD**                                             
   Regressors                    0.28    0.14--0.57    \<0.0001
   CKD stages                                          
   eGFR \>45 ml/min/1.73m^2^     1.00                  
   eGFR 30--45 ml/min/1.73m^2^   2.10    0.58--7.54    0.255
   eGFR \<30 ml/min/1.73m^2^     15.58   4.84--50.18   \<0.0001
  **All-cause death**                                  
   Regressors                    1.16    0.73--1.83    0.540
   CKD stages                                          
   eGFR \>45 ml/min/1.73m^2^     1.00                  
   eGFR 30--45 ml/min/1.73m^2^   0.87    0.44--1.69    0.674
   eGFR \<30 ml/min/1.73m^2^     1.69    0.91--3.14    0.095

Analysis is adjusted for age, gender, diabetes, cardiovascular diseases, BMI, Systolic Blood Pressure, serum levels of phosphate, hemoglobin, uric acid, cholesterol and 24h proteinuria measured at follow up visit.

When we included in the Cox models ΔGFR as continuous variable the relationship with ESRD was not linear; therefore, we performed additional analyses using restricted cubic spline for each CKD stage at follow up visit. The association between ΔGFR and renal risk was modified by stage of disease. As depicted in [Fig 3](#pone.0140138.g003){ref-type="fig"}, in fact, improvement of renal function (positive ΔGFR) was associated to a greater risk of ESRD when GFR\<30ml/min/1.73m^2^ (bottom panel), while the ESRD risk associated to GFR decline (negative ΔGFR) was attenuated from stage 4--5 to stage 3a or higher (see the [Fig 3](#pone.0140138.g003){ref-type="fig"} from bottom to the top).

![Restricted cubic splines to evaluate the non-linear relationship of eGFR change with ESRD at each GFR level: above 45 ml/min/1.73 m^2^ (top), between 30 and 45 ml/min/1.73 m^2^ (middle) and below 30 ml/min/1.73 m^2^ (bottom).\
The reference for the three GFR strata is 0 ml/min/1.73m^2^ when ‎GFR level \>45 ml/min/1.73 m^2^ (top). Spline model is adjusted for age, gender, diabetes, BMI, previous CV disease, smoking, systolic BP, uric acid, hemoglobin, phosphate, cholesterol and 24h proteinuria measured at the follow up visit.](pone.0140138.g003){#pone.0140138.g003}

Discussion {#sec010}
==========

This multicenter cohort study in stage 3--4 CKD patients on long term follow up in Nephrology clinics originally shows that CKD regression, occurs in about one-quarter of cases, it is independent of CKD stage andpredicts a lower risk of ESRD, while not being associated with excess mortality.

The lower incidence of ESRD among CKD regressors (1% per year) is only apparently obvious. Indeed, the change of renal function over time varies considerably and shows a non-linear decline in up to 40% of CKD patients \[[@pone.0140138.ref029]\]; therefore, upward eGFR fluctuations over relatively short periods do not necessarily predict better renal outcomes. By in-depth analysis of this association, we evidenced that renal prognosis in regressors was influenced by the stage of CKD at the start of survival analysis. When considering the level of eGFR reached by patients at the end of the period used for definition of ΔGFR, regressor status was overall associated with a lower risk of ESRD independently from the CKD stage reached ([Table 4](#pone.0140138.t004){ref-type="table"}); however, patients that at the end of eGFR improvement persisted in stage 4 remained exposed to a relatively greater ESRD risk ([Fig 3](#pone.0140138.g003){ref-type="fig"}).

Variability of eGFR in our CKD population is likely attenuated because referred patients under stable nephrology care represent a selected population, that is, more homogeneous as compared to the general CKD population. The cut-off level chosen for defining CKD regressors (ΔGFR≥0 ml/min/1.73 m² within at least two years) was a pragmatic, predefined cut-off which was not based on strict, rigourous methodology like the one applied in the AASK trial population \[[@pone.0140138.ref004]\]. However a loss of 1 ml/min/year is universally considered as kidney loss in healthy subjects \[[@pone.0140138.ref016]--[@pone.0140138.ref018]\]; therefore it is possible to consider as regression also a ΔGFR equal to 0. Yet this pragmatic cut-off is seemingly adequate to predict an excellent renal prognosis, suggesting that the condition of CKD regressor heralds a true, long term, improvement in renal function also outside the trial setting. A recent meta-analysis \[[@pone.0140138.ref015]\], aimed at assessing the association of ΔGFR with subsequent risk of ESRD, has similarly reported an association between improved eGFR and lower risk of ESRD. At variance with that study, however, we also considered proteinuria, causes of CKD, BMI, phosphoremia, uricemia and Hb, as potential confounders of CKD regression. Nephrologist care of CKD patients is associated with better renal outcomes as compared to primary care or other settings \[[@pone.0140138.ref030],[@pone.0140138.ref031]\]. Nevertheless, in studies focusing on the relevance of specialist renal care for the prevention of kidney failure very scanty attention has been dedicated to CKD regression. Improvement in renal function in CKD patients was only incidentally reported in observational studies carried out in settings different from nephrology clinic, such as general population \[[@pone.0140138.ref008],[@pone.0140138.ref009],[@pone.0140138.ref032]\], primary care \[[@pone.0140138.ref007]\] and patients with rheumatoid arthritis \[[@pone.0140138.ref006]\]. In these studies, the entity of eGFR improvement varied widely, from 3% to 33% \[[@pone.0140138.ref004],[@pone.0140138.ref006]--[@pone.0140138.ref009],[@pone.0140138.ref032]\], which likely depends on differences in study design (retrospective or prospective), baseline renal function, inclusion/exclusion criteria, ethnicity and demographic characteristics.

The definition of chronicity of CKD is critical in studies looking at the prognostic value of GFR changes over time. Accordingly, we defined chronicity by a stringent, conservative criterion, i.e., when the diagnosis of CKD was well documented at least 1 year before of study entry. This is important because prolonging the chronicity criterion for CKD definition from 3 to 12 months substantially reduces the number of patients with true CKD \[[@pone.0140138.ref033]\]. Furthermore, since our cohort included patients under stable nephrology care without any recent acute change in eGFR, it is unlikely that short-term functional or hemodynamic worsening of renal function, may have accounted for the subsequent eGFR improvement.

Due to the regression-to-the mean phenomenon, the method we used to assess eGFR change over time, that is, a two-point evaluation, is inherently prone to overestimate the prevalence of CKD regressors. However, this estimate was confirmed in a sensitivity analysis performed in the 82% of the whole cohort where ≥3 eGFR measurements were available during follow up. Al-Aly et al, reported that 38% of 4171 patients with early CKD (eGFR 59--45 ml/min) maintained stable kidney function over a 2.6 year follow-up and similar results were registered by Eriksen et al in CKD stage 3 \[[@pone.0140138.ref006], [@pone.0140138.ref032]\]. These observations suggest that eGFR stability or improvement may be a peculiarity of earlier CKD stages. In line with these findings we also found that the prevalence of CKD regressors in stage 3a was higher than at more advanced CKD stages, even though after multiple adjustments, this association disappeared after multiple adjustments.

Our analysis identified low proteinuria as the strongest factor associated with regressor status. This factor, measured by gold standard, accounted for almost half of the variance of the corresponding logistic model, therefore extending to Caucasian patients the findings obtained in the AASK population \[[@pone.0140138.ref004]\]. However, in our study the association beween proteinuria and the probability of CKD regressor status was not linear and indicated exponentially decreasing odds of regression from 0.5 g/day on ([Fig 2](#pone.0140138.g002){ref-type="fig"}) with the only exception of PKD that was associated with worse renal prognosis independent of proteinuria; this finding may be related to the lower responsiveness to any nephroprotective treatment of these patients \[[@pone.0140138.ref034],[@pone.0140138.ref035]\]. We observed that proteinuria increased in regressors and decreased in non regressors. This difference was of minor entity and, at least in part, dependent on the similar changes in GFR, that increased in regressors and decreased in non regressors.

The lack of relationship between CKD regression and mortality in the present study apparently contrasts with studies reporting a paradoxical link between the eGFR rise and the greater mortality risk \[[@pone.0140138.ref006]--[@pone.0140138.ref009]\]. Our results may depend on the fact that mortality in CKD patients cared by nephrologists is lower than in CKD patients not receiving specialist renal care, as previously reported \[[@pone.0140138.ref010],[@pone.0140138.ref036],[@pone.0140138.ref037]\]. Furthermore, in previous studies the predominance of male sex \[[@pone.0140138.ref006],[@pone.0140138.ref009]\], older age \[[@pone.0140138.ref007]\], black race \[[@pone.0140138.ref006]--[@pone.0140138.ref008]\] and coronary heart disease \[[@pone.0140138.ref006],[@pone.0140138.ref008]\] in apparent CKD regressors may have accounted for higher mortality risk. Finally, the improvement in eGFR in these studies may be at least in part dependent on a decrease in serum creatinine as a result of muscle loss related to coexisting comorbid illness or malnutrition \[[@pone.0140138.ref006]--[@pone.0140138.ref008]\], a phenomenon which seems unlikely in our cohort, as no reduced BMI or serum albumin was registered in CKD regressors.

The present study has limitations. The observational design precludes interpretation of results in causal terms. Furthermore, our findings cannot be generalized to unreferred patients or to ethnic groups other than Caucasians. Moreover, we cannot exclude survival bias that may be present in referred cohorts, and partly suggested by older age and higher prevalence of CVD of patients died during the window time (18--24 months) for evaluation of regressor status. Finally, serum creatinine was not calibrated thus possibly reducing the adequacy of GFR estimates \[[@pone.0140138.ref038],[@pone.0140138.ref039]\]; however, we adopted an established calibration factor to correct creatinine measurement not standardized to isotope dilution mass spectrometry in order to perform CKD-EPI creatinine equation \[[@pone.0140138.ref015],[@pone.0140138.ref021]\].

In conclusion, CKD regression occurs in one-fourth of CKD patients receiving outpatient nephrology care especially in the absence of high proteinuria, hypertension and diagnosis of PKD. Identification of CKD regressors has prognostic relevance because these patients exhibit lower risk of ESRD and no higher risk of death. This phenomenon may be therefore considered in conjunction with main risk factors, including eGFR level reached by patients, in order to optimize renal risk stratification.

Supporting Information {#sec012}
======================

###### Excel format.

(XLSX)

###### 

Click here for additional data file.

List of participating centers {#sec011}
=============================

**TABLE-CKD Study group:** Second University of Naples; Napoli-ASL NA 1; Napoli-University Medical School Federico II; Nola Hospital; Solofra-Hospital; Sapri-Hospital; Benevento-Hospital; Verona-University Medical School; Pisa-University Medical School; Chieti-University Medical School; Matera-Hospital; Putignano-Hospital; Molfetta-Hospital; Manduria-Hospital; Bari-Di Venere Hospital; Bari-University Medical School; Bari-S. Rita Hospital; Galatina-Hospital; Taranto-Hospital; Martina Franca-Hospital; Catanzaro- University Medical School; Reggio Calabria-CNR; Messina-Hospital; Messina-University Medical School; Catania-University Medical School.

**MAURO study group:** Reggio Calabria-CNR, Soverato-Hospital, Locri-Hospital, Cosenza-Hospital, Melito-Hospital, Lungro-Hospital, Messina-Hospita, Crotone-Hospital, Rossano-Hospital, Catanzaro-Pugliese Hospital, Catanzaro- University Medical School, Lamezia-Hospital, S. Giovanni in Fiore-Hospital, Palmi -Hospital, Paola-Hospital, Praia a Mare-Hospital, Catania-University Medical School, Taurianova-Hospital, Vibo Valentia Hospital, Soriano Hospital, Sassari Hospital, Acireale-Hospital.

[^1]: **Competing Interests:**The authors have declared that no competing interests exist.

[^2]: Conceived and designed the experiments: GC RM LDN. Analyzed the data: SB DL PC. Wrote the paper: SB GC CZ DL PC.
